Cargando…
Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
Immunotherapies have an established role in the management of several advanced malignancies. Their responses are largely dependent on the presence of PD-L1, microsatellite instability (MSI), and high tumor mutation burden. Sarcomas are heterogenous tumors which comprise over 100 subtypes. They are b...
Autores principales: | Rytlewski, Jeff, Milhem, Mohammed M., Monga, Varun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267323/ https://www.ncbi.nlm.nih.gov/pubmed/34277839 http://dx.doi.org/10.21037/atm-20-6041 |
Ejemplares similares
-
Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021) -
Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021) -
The dark side of immunotherapy
por: Okwundu, Nwanneka, et al.
Publicado: (2021) -
Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction
por: Florou, Vaia, et al.
Publicado: (2021) -
Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
por: Rytlewski, Jeff, et al.
Publicado: (2022)